Buderer Drug, Imprimis deal

Imprimis acquired IP for wound healing product IPI-120, a transdermal formulation of tranexamic acid and an antibiotic, from compounding pharmacy Buderer. Imprimis believes the formulation can reduce or stop bleeding and prevent or treat infection. Imprimis will develop the product under section 505(b)(2) of the Food, Drug and Cosmetic Act, which allows sponsors to reference data on safety and efficacy from the scientific literature or from previously approved products. Imprimis declined to disclose details. ...